<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387880</url>
  </required_header>
  <id_info>
    <org_study_id>GI 0923 ICE</org_study_id>
    <nct_id>NCT01387880</nct_id>
  </id_info>
  <brief_title>Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer</brief_title>
  <acronym>ICE</acronym>
  <official_title>Phase II Examination of Irinotecan, Cetuximab and Everolimus to Chemotherapy Resistent Patients With Metastatic Colorectal Cancer and KRAS Mutations or After Progression With KRAS Wildtype on Irinotecan and Cetuximab - Effect and Biological Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and&#xD;
      irinotecan every second week combined with a daily dose of everolimus to patients with&#xD;
      metastatic colorectal cancer with Kirsten rat sarcoma viral oncogene (KRAS) mutation or to&#xD;
      patients resistent to cetuximab and irinotecan therapy for metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective:&#xD;
&#xD;
        -  Number of patients with progressive disease that obtain disease control defined as the&#xD;
           sum of patients that obtain a Complete Remission (CR), Partial Remission(PR, or stable&#xD;
           disease (SD))&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Time to progression after first therapy.&#xD;
&#xD;
        -  Length of disease control (CR, PR and SD)&#xD;
&#xD;
        -  Survival from date of start of therapy.&#xD;
&#xD;
        -  Safety and toxicity of the therapy graded according to Common Toxicity Criteria version&#xD;
           3.0&#xD;
&#xD;
        -  Influence of smoking on disease control, response, survival and time to progression and&#xD;
           other effect parameters in the investigation.&#xD;
&#xD;
        -  Significance of metabolic response evaluated by a Photon Emissions Tomography&#xD;
           (PET)/Computer Tomography(CT)scan.&#xD;
&#xD;
        -  Blood: Examine the influence of potential predictive and prognostic tumour biomarkers in&#xD;
           blood as lactate dehydrogenase (LDH), Carcinoembryonic antigen (CEA), Vascular&#xD;
           endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), Human&#xD;
           Epidermal growth factor Receptor 2 (HER-2), YKL-40, Interleukin-6 (IL-6)&#xD;
           ,metallopeptidase inhibitor 1 (TIMP-1), procollagen type I N-terminal propeptide (PINP),&#xD;
           Procollagen type 3 N-terminal propeptide (P3NP), gen-, micro-ribonucleinate (microRNA)-&#xD;
           and protein array profiles, metabolomics and C-reactive protein (CRP) 2 weeks after&#xD;
           start of therapy and thereafter every 8.weeks on disease control, response, survival and&#xD;
           time to progression and other parameters investigated.&#xD;
&#xD;
        -  Tissue: Examine possible predictive and prognostic biomarkers in tissue from primary&#xD;
           tumour or metastases for micro-RNAarray profiles, mutations in K-RAS, murine sarcoma&#xD;
           viral oncogene homolog (BRAF), Phosphoinositide 3-kinase (PIK3CA), EGFR, tumor protein&#xD;
           53 (p53), and protein expression and polymorphisms of th phosphatase and tensin homolog&#xD;
           (PTEN), epiregulin (EREG), amphiregulin (AREG), Insulin-like growth factor 1 (IGF-1),&#xD;
           IGF-1 Receptor (IGF-1R), VEGF, p53, topoisomerase 1 (Topo1), YKL-40, and TIMP-1&#xD;
&#xD;
        -  Correlation between possible predictive and prognostic biomarkers in blood and tissue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit (SD+PR+CR)</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical benefit is defined as the number of patients with stable disease lasting 2 months and partial response and CR as defined in RECIST 1.1</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab, everolimus, irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab, everolimus and Irinotecan.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.&#xD;
Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.&#xD;
Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan.</description>
    <arm_group_label>Cetuximab, everolimus, irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>1.66 mg per day up to 7Â½ mg per day</description>
    <arm_group_label>Cetuximab, everolimus and Irinotecan.</arm_group_label>
    <arm_group_label>Cetuximab, everolimus, irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for inclusion:&#xD;
&#xD;
          -  Patients with a histological or cytological verified adenocarcinoma of the colon or&#xD;
             rectum with non-resectable or metastatic cancer.&#xD;
&#xD;
          -  Patients with measurable disease without previous radiotherapy&#xD;
&#xD;
          -  Patients with metastatic colorectal cancer with progression after previous therapy&#xD;
             with 5-fluoropyrimidines, oxaliplatin or irinotecan. Patients should have been treated&#xD;
             with oxaliplatin, but if oxaliplatin has be contraindicated or not tolerated the&#xD;
             patient can participate in the trial.&#xD;
&#xD;
          -  Patients with KRAS-mutation in their primary tumour or metastasis.&#xD;
&#xD;
          -  Patients with progression after therapy with irinotecan or cetuximab independent of&#xD;
             KRAS mutation status.&#xD;
&#xD;
          -  Previous radiotherapy is allowed to less than 25 % of the bone marrow.&#xD;
&#xD;
          -  Age more or equal to 18 years.&#xD;
&#xD;
          -  Performance status less than 3.&#xD;
&#xD;
          -  An expected survival time of at least 3 months.&#xD;
&#xD;
          -  Signed informed consent according to specifications from the ethical comites.&#xD;
&#xD;
        Criteria for exclusion:&#xD;
&#xD;
          -  Former or other concurrent malignant disease except treated basal cell carcinoma or in&#xD;
             situ cervical cancer.&#xD;
&#xD;
          -  No cytotoxic therapy or other experimental treatment within 28 days before inclusion.&#xD;
&#xD;
          -  No former therapy with everolimus or other rapamycin as sirolimus or temsirolimus.&#xD;
&#xD;
          -  No known hypersensitivity for one or more components in the therapy.&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No serious non-healing wounds, gastric ulcers, bone fractures, greater surgical&#xD;
             procedures, major traumatic injuries within 28 days before inclusion.&#xD;
&#xD;
          -  No ongoing bleeding or pathological condition associated with a risk of bleeding.&#xD;
&#xD;
          -  No liver disease as cirrhose, chronical active hepatitis or chronic persistent&#xD;
             hepatitis.&#xD;
&#xD;
          -  No gastrointestinal disturbances in function that might cause a major change in the&#xD;
             absorption of everolimus as ulcerative disease, uncontrolled nausea, vomiting,&#xD;
             diarrhoea, malabsorption syndrome.&#xD;
&#xD;
          -  No planned immunisation with attenuated virus in the study period.&#xD;
&#xD;
          -  Patients that is unable to follow treatment or evaluation plan.&#xD;
&#xD;
          -  Every condition or therapy that after the judgement of investigator might infer the&#xD;
             patient a risk or influence the trials objective.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  At fertile women this is insured by a negative test of pregnancy or use of a safe&#xD;
             anticonception during the trial period and at least 3 months after end of treatment.&#xD;
&#xD;
          -  Patients with active infections or other serious medical co-morbidity, that might&#xD;
             prevent the patient from being treated with the protocoled therapy.&#xD;
&#xD;
          -  Incapacitated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benny V Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Copenhagen</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>March 18, 2012</last_update_submitted>
  <last_update_submitted_qc>March 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Benny Vittrup Jensen</investigator_full_name>
    <investigator_title>onsultant</investigator_title>
  </responsible_party>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>Third line therapy</keyword>
  <keyword>Fourth line therapy</keyword>
  <keyword>KRAS mutation status</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

